镰状细胞病和铁过载患者的铁螯合疗法。 - Suppr

Iron chelation therapy for patients with sickle cell disease and iron overload.

作者信息

Inati Adlette, Khoriaty Evelyne, Musallam Khaled M, Taher Ali T

机构信息

Division of Pediatric Hematology and Oncology, Children's Centre for Cancer and Blood Diseases, Rafik Hariri University Hospital, Beirut, Lebanon.

出版信息

Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.

DOI:10.1002/ajh.21806

PMID:20721892

Abstract

摘要

相似文献

Iron chelation therapy for patients with sickle cell disease and iron overload.

Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.

Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.

Am J Hematol. 2010 Jun;85(6):460-1. doi: 10.1002/ajh.21711.

Iron-chelating therapy for transfusional iron overload.

N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.

[Pathogenesis of transfusional iron overload and iron chelation therapy].

Rinsho Ketsueki. 2009 Jul;50(7):527-31.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.

Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.

Iron chelation therapy in the management of transfusion-related cardiac iron overload.

Transfusion. 2012 Oct;52(10):2256-68. doi: 10.1111/j.1537-2995.2012.03580.x. Epub 2012 Mar 8.

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Ann N Y Acad Sci. 2005;1054:350-7. doi: 10.1196/annals.1345.043.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Cochrane Database Syst Rev. 2010 Aug 4(8):CD007477. doi: 10.1002/14651858.CD007477.pub2.

引用本文的文献

Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers.

Adv Wound Care (New Rochelle). 2018 Oct 1;7(10):323-332. doi: 10.1089/wound.2018.0789. Epub 2018 Oct 11.

Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

PLoS One. 2014 Jan 9;9(1):e85271. doi: 10.1371/journal.pone.0085271. eCollection 2014.

Sickle cell disease in children.

Drugs. 2012 May 7;72(7):895-906. doi: 10.2165/11632890-000000000-00000.

Chelation therapy for iron overload: nursing practice implications.

J Infus Nurs. 2011 Nov-Dec;34(6):374-80. doi: 10.1097/NAN.0b013e3182306356.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Iron chelation therapy for patients with sickle cell disease and iron overload.

作者信息

Inati Adlette, Khoriaty Evelyne, Musallam Khaled M, Taher Ali T

机构信息

Division of Pediatric Hematology and Oncology, Children's Centre for Cancer and Blood Diseases, Rafik Hariri University Hospital, Beirut, Lebanon.

出版信息

Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.

DOI:10.1002/ajh.21806

PMID:20721892

Abstract

摘要

相似文献

Iron chelation therapy for patients with sickle cell disease and iron overload.

Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.

Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.

Am J Hematol. 2010 Jun;85(6):460-1. doi: 10.1002/ajh.21711.

Iron-chelating therapy for transfusional iron overload.

N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.

[Pathogenesis of transfusional iron overload and iron chelation therapy].

Rinsho Ketsueki. 2009 Jul;50(7):527-31.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.

Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.

Iron chelation therapy in the management of transfusion-related cardiac iron overload.

Transfusion. 2012 Oct;52(10):2256-68. doi: 10.1111/j.1537-2995.2012.03580.x. Epub 2012 Mar 8.

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Ann N Y Acad Sci. 2005;1054:350-7. doi: 10.1196/annals.1345.043.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Cochrane Database Syst Rev. 2010 Aug 4(8):CD007477. doi: 10.1002/14651858.CD007477.pub2.

引用本文的文献

Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers.

Adv Wound Care (New Rochelle). 2018 Oct 1;7(10):323-332. doi: 10.1089/wound.2018.0789. Epub 2018 Oct 11.

Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

PLoS One. 2014 Jan 9;9(1):e85271. doi: 10.1371/journal.pone.0085271. eCollection 2014.

Sickle cell disease in children.

Drugs. 2012 May 7;72(7):895-906. doi: 10.2165/11632890-000000000-00000.

Chelation therapy for iron overload: nursing practice implications.

J Infus Nurs. 2011 Nov-Dec;34(6):374-80. doi: 10.1097/NAN.0b013e3182306356.

Iron chelation therapy for patients with sickle cell disease and iron overload.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Iron chelation therapy for patients with sickle cell disease and iron overload.

作者信息

机构信息

出版信息

相似文献

引用本文的文献